From Citizendium
Jump to navigation Jump to search
This article is developing and not approved.
Main Article
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
This editable Main Article is under development and subject to a disclaimer.

Tigecycline is the first commercially available antibiotic of the glycylcycline class, which are a new family based on tetracyclines, but with molecular modifications to evade some, but not all, tetracycline resistance mechanisms. [1] Tetracycline resistance... [2]

Its labeled indications are:[3]

  • Complicated Appendicitis
  • Complicated Bacterial Peritonitis
  • Complicated Skin and Skin Structure Infection
  • Complicated Skin and Skin Structure E. coli Infection
  • Complicated Skin and Skin Structure Enterococcus faecalis Infection,

  • Infectious Disease of Abdomen
  • Intra-Abdominal Abscess*
  • Legionella pneumophila Pneumonia
  • Streptococcal Pneumonia

Mechanism of action

The drug evades the Tet(A-E) efflux pumps[4] which account for most acquired resistance to tetracycline and minocycline in Enterobacteriaceae and Acinetobacter spp.; also the Tet(K) pumps, which occur widely in staphylococci conferring resistance to tetracycline though not minocycline or doxycycline.[2] It binds to bacterial ribosomes that have been modified by the Tet(M) protein,Cite error: Closing </ref> missing for <ref> tag


It is given intravenously, but should not be administered simultaneously, through common tubing, with amphotericin B, chlorpromazine, methylprednisolone, or voriconazole.


  1. David M. Livermore (2005), "Tigecycline: what is it, and where should it be used?", Journal of Antimicrobial Chemotherapy 56 (4): 611-614, DOI:10.1093/jac/dki291
  2. 2.0 2.1 Chopra I (1986), "Genetic and biochemical basis of tetracycline resistance", J Antimicrob Chemother 18 (Suppl C): 51–6
  3. Tigecycline IV, American Society of Health-System Pharmacists
  4. Petersen PJ, Jacobus NV, Weiss WJ et al (1999), "In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)", Antimicrob Agents Chemother 43: 738–44